Giant right atrial thrombus: a life-threatening complication of long-term central venous access catheters

Early onset of cooling catheter-related right atrial thrombus following cardiac arrest

Catheter-related right atrial thrombus (RAT) is an uncommon life-threatening complication. Few cases of endovascular cooling catheter–related complications have been reported. We report the first case of endovascular cooling catheter–related RAT. A 17-year-old adolescent boy was treated with therapeutic hypothermia using an endovascular cooling catheter following ventricular fibrillation cardiac arrest. He became alert, but RAT was found 3 days after the placement of the cooling catheter. Anticoagulation with enoxaparin for 2 weeks completely resolved the RAT, and he was consequently treated with radiofrequency ablation and received an implanted cardiac defibrillator. This case report highlights the occurrence of endovascular cooling catheter–related RAT early after the placement of a catheter. Physicians should monitor whether RAT occurs during and following therapeutic hypothermia with a cooling catheter.

Giant right atrial thrombi treated with thrombolysis

The present report describes giant atrial thrombi that were treated with thrombolysis in a community hospital. Two patients with giant atrial thrombi whose treatment involved complications are presented. Both patients developed cardiogenic shock and were treated unsuccessfully with thrombolysis. Because thrombolysis of giant thrombi may be ineffective, patients in this situation may require surgery.

UNRESOLVED ISSUES IN DIALYSIS: Long-Term Management of the Tunneled Venous Catheter

Despite their propensity for significant complications, tunneled central venous catheters have become a common means of vascular access in the United States for patients requiring maintenance hemodialysis for end-stage renal disease (ESRD). Reasons for their use include advanced patient age, peripheral vascular disease (arterial and venous), late referral for creation of vascular access, and more importantly, the lack of an interdisciplinary service line on vascular access among vascular surgeons, radiologists, and nephrologists. This review article summarizes complications commonly encountered in dialysis patients who use tunneled central venous catheters for vascular access-mainly thrombosis, stenosis, and infection. Special attention is given to novel approaches for the prevention of catheter-associated infections. Effective prevention and timely treatment of common catheter-associated complications can reduce the substantial morbidity associated with the use of these devices. However, these measures should not detract from the goal of avoiding or limiting the long-term use of catheters, thereby optimizing vascular access management by ensuring the timely availability of functioning arteriovenous fistulas.

Catheter thrombosis

Catheter malfunction due to poor flow is a common problem. When it occurs early, the cause is generally technical. Late occurrences are most often related to thrombus formation. Several types of thrombus may be seen, differing by location and supposed mechanism of formation. The most common offender, however, is the fibrin sheath thrombus. Prevention of catheter malfunction is an endeavor that continues to beg many questions. Catheter malfunction should be treated early to avoid inadequate dialysis. In the past, urokinase was a highly valuable aid to the nephrologist in managing this problem. Since this agent became unavailable a suitable alternative has not emerged. Recombinant tissue plasminogen activator (tPA) seems to be the most likely candidate for this role; however, it is not currently available in a packaging form that is optimal for this purpose. Currently, catheter exchange appears to be the best available alternative for this problem, which cannot yet be resolved by simpler means.

Temporary vascular access for extracorporeal therapies

Central venous catheters provide at the present time the basic and ideal method to perform acute extracorporeal blood purification. Rapid launch of extracorporeal therapy is indicated in two situations: first, renal conditions presenting as a recognized acute organic renal failure (ARF) and acute decompensation of end stage renal disease (ESRD) without permanent vascular access; second, non-renal conditions presenting as urgent clinical situations requiring isolated ultrafiltration for chronic congestive heart failure, plasmapheresis or selective immunoadsorption for immune diseases, cytapheresis for hematological disease, and selective detoxification for certain types of poisoning. Central venous catheters are classified into 2 categories according to the duration of use: temporary catheter (less than 90 days) and permanent catheter (more than 90 days). A temporary catheter, including rigid (polyethylene, teflon) and semirigid (polyurethane) material, is indicated in emergency situations and for short-term use. A permanent catheter, made usually of soft silicone rubber with a subcutaneous anchoring system, has a subcutaneous tunnel and is indicated in medium and long-term use. Catheter design has benefited greatly from technical advances and material hemocompatability. However, catheter-related morbidity still remains high and is associated with an unacceptable incidence rate of infection and/or vein thrombosis. This article covers our present knowledge regarding catheter indications, technical aspects of catheter insertion and care, functional limitation of central venous catheters, and catheter-related complications. It is also our intent to provide the reader with optimal indication and catheter care in order to prevent and reduce the burden of catheter-related morbidity.